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Birt–Hogg–Dube ´ (BHD) syndrome is an inherited cancer
susceptibility disease characterized by skin and kidney
tumors, as well as cystic lung disease, which results from
loss-of-function mutations in the BHD gene. BHD is also
inactivated in a signiﬁcant fraction of patients with
sporadic renal cancers and idiopathic cystic lung disease,
and little is known about its mode of action. To investigate
the molecular and cellular basis of BHD tumor suppressor
activity, we generated mutant Bhd mice and embryonic
stem cell lines. BHD-deﬁcient cells exhibited defects in
cell-intrinsic apoptosis that correlated with reduced
expression of the BH3-only protein Bim, which was
similarly observed in all human and murine BHD-related
tumors examined. We further demonstrate that Bim
deﬁciency in Bhd
 /  cells is not a consequence of elevated
mTOR or ERK activity, but results instead from reduced
Bim transcription associated with a general loss of TGFb-
mediated transcription and chromatin modiﬁcations. In
aggregate, this work identiﬁes a speciﬁc tumor suppressive
mechanism for BHD in regulating TGFb-dependent
transcription and apoptosis, which has implications for
the development of targeted therapies.
Oncogene (2011) 30, 2534–2546; doi:10.1038/onc.2010.628;
published online 24 January 2011
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Introduction
Birt–Hogg–Dube ´ (BHD) syndrome is a rare inherited
cancer susceptibility disease characterized by benign
hair follicle tumors and lung cysts in a majority of
patients, and renal cell carcinoma (RCC) in approxi-
mately one third of diagnosed BHD cases (Schmidt
et al., 2005). Genetic analyses of families affected by
BHD syndrome previously identiﬁed germline muta-
tions in the BHD gene on chromosome 17p11.2, most of
which were predicted to prematurely truncate the
encoded protein (Nickerson et al., 2002; Toro et al.,
2008). Mutational analyses of BHD-related tumors
from patients, as well as those from mouse and rat
models of BHD syndrome, identiﬁed inactivating
‘second hits’ in the remaining wild-type BHD allele,
formally establishing BHD as a tumor suppressor
(Okimoto et al., 2004; Vocke et al., 2005; Hasumi
et al., 2009). BHD inactivation has also been described
in a subset of von Hippel–Lindau-independent RCC
syndromes, in approximately one third of sporadic renal
cancers, and in 60% of idiopathic cystic lung disease
cases (Khoo et al., 2003; Gunji et al., 2007; Woodward
et al., 2008).
While the genetic basis of BHD syndrome is well
understood, the cellular and molecular mechanisms
involving the protein encoded by BHD, also called
Folliculin, remain unclear. Dissecting BHD’s molecular
functions is particularly challenging since the BHD gene
product bears no sequence or functional homology to
any known protein. Studies in Schizosaccharomyces
pombe have suggested a role for the putative yeast
BHD ortholog in amino-acid homeostasis, while siR-
NA-mediated knockdown of Drosophila BHD in the
ﬂy has implicated it in male germline stem cell
maintenance through Stat and/or BMP signaling (Singh
et al., 2006; van Slegtenhorst et al., 2007). Finally,
mammalian cell culture analyses and mouse models
have linked BHD and mammalian target of rapamycin
(mTOR) signaling, potentially mediated through an
interaction with its binding partner, called Folliculin-
interacting protein, and AMP-activated kinase (Baba
et al., 2006). These studies demonstrate that BHD loss
can paradoxically result in either stimulation or inhibi-
tion of mTOR depending on the system examined (Baba
et al., 2006, 2009; Hudon et al., 2008, 2010).
To investigate the cellular and molecular mechanisms
by which BHD suppresses tumorigenesis, we established
Bhd
 /  embryonic stem (ES) cell lines, since the early
lethality of Bhd
 /  embryos precluded the development
of other cellular models. We observed that the major
cellular consequence of BHD loss is resistance to
apoptosis caused by decreased Bim expression. This
phenomenon was independent of mTOR and ERK
hyperactivation and was instead associated with a
general loss of TGFb-dependent chromatin modiﬁca-
tions and transcription. These data present new insight
into how BHD functions as a tumor suppressor and
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Results
Homozygous mutant Bhd embryos die during early
embryogenesis
To deﬁne the basic molecular functions of BHD, we
initially attempted to establish mouse embryonic ﬁbro-
blasts from a gene-trap mouse model. In order to fully
characterize this mutant Bhd allele (denoted as m),
we mapped the insertional position of the trap cas-
sette to intron 8 of the murine Bhd gene, and estab-
lished Southern and PCR-based genotyping assays to
discriminate wild type from the m allele (Figures 1a–c).
Using multiple quantitative real-time (qRT)–PCR
probes, we observed a 40–50% reduction in Bhd mRNA
expression in Bhd
þ/m ES cells compared with Bhd
þ/þ
controls by qRT–PCR (Figure 1d), and conﬁrmed
expression of the BHD–bgeo fusion product by staining
the ES cells with X-Gal (Figure 1e).
Bhd
þ/m intercrosses yielded no viable Bhd
m/m embryos
after e7.5; although we were unable to genotype e6.5
embryos, we observed that B25% of these were severely
abnormal or partially resorbed upon dissection, exhibit-
ing grossly atrophied and disorganized egg cylinders,
distorted visceral endoderm and lack of cavitation
(Figures 1f and g). This phenotype is consistent with a
recently reported embryonic lethal phenotype for an
independent mutant Bhd allele (Hasumi et al., 2009).
Figure 1 Bhd
m/m embryos are early embryonic lethal. (a) Schematic depicting integration site of Bay Genomics pG2Lxf gene-trap
vector in murine Bhd intron 8, location of probe and restriction sites for Southern blot genotyping and location of primers (P1, P2, and
P3) for PCR-based genotyping. (b) Southern blot of PvuII-digested genomic DNA and (c) PCR-based genotypes of Bhd
þ/þ or Bhd
þ/m
ES cells to discriminate wild-type from mutant alleles. ‘m’ speciﬁcally designates the gene-trapped mutant Bhd allele from Bay
Genomics throughout the manuscript. (d) Relative Bhd mRNA levels in Bhd
þ/þ versus Bhd
þ/m ES cells assayed by qRT–PCR using
primers spanning exons just downstream of the trap cassette (exons 9–10) or across the terminal exons of the Bhd gene (exons
12–13), ruling out the presence of aberrant transcripts generated from cryptic transcriptional start sites downstream of the trap
cassette. (e) X-Gal staining of Bhd
þ/þ and Bhd
þ/m ES cells showing Bhd
þ/m cells express the Bhd-b-galactosidase fusion product.
(f) Table of progeny obtained from Bhd
þ/m intercrosses showing no Bhd
 /  embryos could be recovered after e6.5. (g) 200 images
of H&E-stained cross-sections of parafﬁn-embedded e6.5 embryos from Bhd
þ/m intercrosses. (A) Exempliﬁes normal morphology while
(B) and (C) demonstrate gross abnormalities, probable Bhd
m/m genotypes.
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OncogeneLoss of BHD does not affect proliferation, but results
in decreased cellular size and resistance to cell-intrinsic
apoptosis
Since the early lethality of the Bhd
m/m embryos precluded
the development of differentiated cell types, we generated
an ES cell model for in vitro studies. To do this, we used
an independent mutant Bhd allele (denoted as ‘–’) with a
gene trap in Bhd intron 1, which ablated expression of the
entire Bhd open reading frame. The Bhd
þ/  ES cells were
characterized in the same manner as the Bhd
þ/m cells to
validate efﬁcacy of the trap cassette (Supplementary
Figures 1a–e).
Bhd
 /  ES cells were generated from the parental Bhd
þ/ 
cells as shown by PCR, and western blot conﬁrmed
complete loss of BHD protein expression (Figures 2a and
b). To verify BHD loss did not affect the undifferentiated
state of Bhd
 /  ES cells, we analyzed protein levels
of Oct-4, Nanog, Sox2 and phospho-Stat3, and alkaline
phosphatase activity in Bhd
þ/þ, Bhd
þ/ , and Bhd
 / 
cells (Supplementary Figures 2a–c). We observed no
difference in all parameters of ES cell pluripotency,
allowing for valid comparison in in vitro studies across
genotypes.
To gain insight into BHD’s tumor suppressive proper-
ties, we assessed Bhd
þ/þ, Bhd
þ/ ,a n dBhd
 /  ES cell lines
for proliferation, cell growth, and apoptotic responses.
Bhd
 /  ES cells did not proliferate signiﬁcantly faster at
days 1–3 after plating, but conﬂuent cultures analyzed at
day 4 were found to contain 15–20% more cells compared
with Bhd
þ/þ and Bhd
þ/  counterparts (Figure 2c).
Intriguingly, this difference was attributed to a 15–20%
decrease in cellular volume in Bhd
 /  cells (Figure 2d).
Finally, we evaluated the response of Bhd
 /  cells to
cell-intrinsic apoptosis by starving cells of serum, glucose,
or amino acids for 24h. Bhd
 /  cells clearly demon-
strated a resistance to all three apoptosis-inducing
stresses as revealed by light microscopy, decreased
accumulation of sub-G1 populations, and reduced
Caspase-3 and Parp cleavage (Figures 2e–h). This
effect was speciﬁc to the intrinsic apoptotic pathway,
as Bhd
 /  cells showed no differential response to the
death-receptor ligand Tumor necrosis factor a
(Figure 2g). Thus, BHD deﬁciency does not confer an
obvious increase in cellular proliferation or growth, but
does reduce cell-intrinsic apoptosis, thereby identifying
a plausible cellular role for BHD as a tumor suppressor.
Bim expression is lost in Bhd
 /  cells and BHD-related
tumors and contributes to apoptotic resistance
The cell-intrinsic apoptotic resistance of Bhd
 /  cells could
either be due to increased intracellular nutrient stores, an
effect previously observed in a mutant yeast model of
BHD, or result from a defect in the cell-intrinsic death
machinery (van Slegtenhorst et al., 2007). To assess the
former possibility, we measured levels of 13 different
intracellular amino acids by high performance liquid
chromatography and observed no differences between
Bhd
þ/þ and Bhd
 /  ES cells, suggesting that nutrient
homeostasis was not playing a role in the apoptotic-
resistance phenotype (Figure 3a).
To determine if the cell-intrinsic death machinery
might be impaired in Bhd
 /  ES cells, we examined
protein levels of several Bcl2 family members and found
many pro-apoptotic BH3-only proteins to be misregu-
lated in Bhd
 /  cells. Both extra-long (EL) and long (L)
isoforms of Bim, as well as Pumaa and Bad were
signiﬁcantly downregulated in Bhd
 /  ES cells, while Bid
and BMF levels were upregulated (Figure 2b). Bik,
Noxa, and Pumab, as well as the multi-domain Bcl2
family members BclXL and Bak were unchanged.
Similar results were obtained using three independent
BHD-deﬁcient ES clones homozygous for the Bhd
m
allele (Supplementary Figures 3a and b). We focused
primarily on Bim regulation in subsequent experiments,
given its dominant role among BH3-only proteins in
mediating the cell-intrinsic death response and frequent
loss in RCC (Kim et al., 2006; Zantl et al., 2007; Guo
et al., 2009).
To test whether the apoptotic resistance of Bhd
 / 
cells was Bim dependent, we restored either BimEL or
Bhd expression by retroviral transduction in Bhd
 /  cells.
Restoration of BimEL or Bhd expression, or treatment
of cells with the BH3-only chemical mimetic ABT-737,
rescued the apoptotic response of Bhd
 /  ES cells to
amino-acid deprivation, as assessed by FACs analysis
(Figure 3c, upper panel), and Parp and Caspase-3
cleavage (Figure 3c, lower panel). Importantly, Bhd
reconstitution was sufﬁcient to restore Bim protein
levels. Interestingly, autophagy inhibitors 3-methyl-
adenine and chloroquine rescued the apoptotic response
in Bhd
 /  cells (Figure 3c), similar to apoptosis-deﬁcient
Bax
 / /Bak
 /  double knockout cells (Lum et al., 2005).
To determine whether loss of BHD results in Bim
deﬁciency in vivo, we performed immunohistochemistry
on BHD-related tumors from both human BHD
patients and aged Bhd
þ/m mice. 3/3 human-derived
tumors (one ﬁbrofolliculoma, one chromophobe-clear
cell hybrid RCC, and one chromophobe RCC) and 5/5
solid murine renal tumors (four hybrid oncocytic
and one papillary mass projecting from a cyst),
exhibited absent or signiﬁcantly reduced Bim expres-
sion, conﬁrming that loss of Bim expression is a
common event in BHD-related tumors of diverse
histologies (Figure 3d).
Bim is transcriptionally downregulated in Bhd
 / 
cells independent of mTORC1, mTORC2, ERK,
or GCN2-eIF2a pathway aberrations
Bim is regulated transcriptionally by several well-
characterized signal transduction pathways, translation-
ally by miRNAs, and on the level of protein stability
(Dijkers et al., 2000; Dehan et al., 2009; Su et al., 2009).
We initially assessed Bim mRNA and found it to be
decreased by B80% in Bhd
 /  cells compared with
Bhd
þ/þ and Bhd
þ/  cells (Figure 4a). To investigate a
possible additional role for enhanced proteolytic degra-
dation of Bim, we treated Bhd
 /  cells with the
proteasome inhibitor MG-132, but observed no increase
in Bim protein (Supplementary Figure 4a) (Dehan et al.,
2009). We also examined levels of mir-19 and mir-92,
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OncogenemiRNAs previously shown to regulate Bim translation
in ES cells (Su et al., 2009), but detected no differences
between Bhd
 /  and control cells (Supplementary
Figure 4b).
To determine which transcriptional networks and
upstream signaling pathways were involved in Bim
misregulation, we investigated the mTOR and ERK
pathways that have previously been linked to Bim
regulation (Dijkers et al., 2000; Dehan et al., 2009), and
are hyperactivated in late-stage cysts and tumors derived
from a mutant Bhd mouse model (Baba et al., 2008).
Western blot analysis of Bhd
þ/þ, Bhd
þ/ ,a n dBhd
 /  ES
cells revealed that Bhd
 /  ES cells exhibited hyperpho-
sphorylation of S6K1 and 4E-BP1 (indicative of
increased mTOR complex 1 (mTORC1) activity),
hyperphosphorylation of Akt and the FoxO family of
Figure 2 Bhd
 /  ES cells do not have a proliferative or growth advantage, but are resistant to apoptosis. (a) PCR genotypes verifying
loss of wild-type Bhd allele in three independent ES clones, designated as ‘1’, ‘2’, and ‘3,’ after step-up selection. WT=wild-type,
Mut=mutant alleles. (b) Western blot demonstrating loss of BHD protein expression in three independent Bhd
 /  ES clones with a
non-speciﬁc (NS) band shown as a loading control. (c) Growth curve showing Bhd
 /  ES cells proliferate at similar rates to Bhd
þ/þ and
Bhd
þ/  counterparts, but have increased saturation density at day 4. (d) Coulter counter size measurements showing Bhd
 /  cells are
signiﬁcantly smaller than Bhd
þ/þ and Bhd
þ/  ES cells (*P¼0.000623). Bhd
 /  ES cells are resistant to stress-induced apoptosis as
shown by (e) brightﬁeld images of Bhd
þ/þ and Bhd
 /  ES cells starved of amino acids for 1 day, or (g) FACs analysis of cells containing
sub-G1 DNA content after 1 day serum, glucose and amino-acid (AA) deprivation compared with Bhd
þ/þ and Bhd
þ/  cells
(*Po0.0000345), but not by Tumor necrosis factor a treatment. (f) Representative FACs plot showing Bhd
 /  ES cells have
signiﬁcantly less sub-G1 DNA content following 1 day of amino-acid starvation. (h) Western blot of Caspase and Parp cleavage with
and without amino-acid starvation in Bhd
þ/þ and Bhd
 /  ES cells. All bar graphs represent averages of three independent experiments
with error bars showing standard error of the mean (s.e.m.).
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Oncogeneproteins (indicative of mTOR complex 2 (mTORC2)
hyperactivation) and hyperactivation of the MEK–
ERK–p90RSK cascade (Figure 4b).
To determine if these pathways were playing a role in
decreased Bim levels in Bhd
 /  cells, we treated cells with
inhibitors of each at doses that reduced signaling in
Bhd
 /  cells to levels observed in Bhd
þ/þcells. We found
that pharmacologic inhibition of PI3K-dependent
mTORC2, MEK, or mTORC1 activities, either singly or
in combination, was insufﬁcient to restore Bim protein
levels in Bhd
 /  cells (Figure 4c). Treatment of Bhd
 /  cells
with the same panel of inhibitors was similarly unable to
rescue the death-resistance phenotype as assessed by sub-
G1 population quantiﬁcation (Figure 4d, upper panel), or
Caspase and Parp cleavage following 2-day amino-acid
starvation (Figure 4d, lower panel).
Bim expression is also known to be regulated by
Chop, a transcription factor activated downstream of
Figure 3 Death resistance of Bhd
 /  cells is not due to increased intracellular amino-acid levels, but instead results from decreased Bim
protein levels. (a) Intracellular amino-acid levels normalized to total protein in Bhd
þ/þ versus Bhd
 /  ES cells as assessed by HPLC.
Data represent average of three independent experiments and error bars reﬂect standard deviation. (b) Western blot showing Bhd
 /  ES
cells have decreased levels of several BH3-only proteins, most notably Bim. (c) Quantiﬁcation of sub-G1 populations by ﬂow cytometry
in upper panel shows restoration of Bhd and BimEL expression, or treatment with ABT-737 (ABT), chloroquine (CQ) or 3-methyl-
adenine (3MA) rescues the death-resistance phenotype of Bhd
 /  ES cells in response to 2-day amino-acid starvation compared with
untreated or vector only (MSCV) infected controls. Bar graph represents three independent experiments and error bars show s.e.m.
Lower panel is a western blot verifying re-expression of BHD and Bim, and correlate changes in Caspase-3 and Parp cleavage.
(d) 200  images of parafﬁn-embedded sections of solid renal tumors (labeled T) from Bhd
þ/m mice 18–21 months in age (A–C)o ra
human patient (D) exhibiting loss of Bim expression compared with normal adjacent tissue (labeled N). (A–C) Hybrid clear cell-
oncocytic lesions from aged Bhd
þ/m mice and (D) is a human chromophobe RCC.
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Oncogeneeukaryotic initation factor a (eIF2a) kinases as part of
the unfolded protein response and as an adaptation to
nutrient withdrawal (Puthalakath et al., 2007). Interest-
ingly, Bhd
 /  cells exhibited decreased basal and amino-
acid deprivation-induced levels of p-eIF2a levels, but
not ER stress-induced p-eIF2a after thapsigargin treat-
ment (Supplementary Figures 5a–c). However, induc-
tion of the downstream effectors ATF4 and Chop was
only slightly attenuated in response to amino-acid
deprivation (Supplementary Figure 5b). More impor-
tantly, reintroduction of Chop into Bhd
 /  cells failed to
rescue Bim expression (Supplementary Figure 5d).
Collectively, these data suggest that the downregulation
of Bim and apoptotic resistance observed in Bhd
 /  cells
are not due to signaling aberrations in the mTORC1,
mTORC2, ERK, and eIF2a signaling pathways.
Bhd
 /  ES cells exhibit many phenotypic and molecular
defects characteristic of TGFb-pathway mutants
We next considered the TGFb pathway, since many
reports had previously shown it regulated Bim
Figure 4 Bim is transcriptionally downregulated in Bhd
 /  cells independent of mTORC1, mTORC2, or ERK hyperactivation.
(a) qRT–PCR analysis showing Bim mRNA is reduced in Bhd
 /  ES cells (*P¼1.44 10
 7). (b) Western blot demonstrating that
mTORC1 (indicated by p-S6K1 [T389] and p-4E-BP1 [T70]), mTORC2 (indicated by p-Akt [S473] and p-FoxO [FoxO1 (Thr24]/
FoxO3a [Thr32]/Fox04 [Thr28]) and ERK (indicated by p-MEK [S217/271], p-ERK [T202/Y204], and p-p90RSK [T359/S363])
signaling pathways are hyperactivated in Bhd
 /  ES cells. (c) Inhibition of hyperactivated mTORC2 by 5mM LY294002 (LY) or ERK
by 10mM PD98059 (PD) or a combination of both, or inhibition of mTORC1 by 20nM rapamycin (rapa) for 24h does not restore Bim
protein expression levels in Bhd
 /  cells by western blot. Drug efﬁcacy was shown by decreased p-FOXO levels with LY treatment and
decreased p-ERK levels with PD treatment in Bhd
 /  cells. Decreased mobility shifts in S6K demonstrate effectiveness of both LY and
rapa treatments. Doses were chosen based on their ability to bring activation levels of signaling components in Bhd
 /  cells to those
observed in Bhd
þ/þ cells. (d) Bhd
 /  ES cells were pre-treated for 6h with the same panel of inhibitors as (c), then starved of amino
acids for 2 days with inhibitors re-added after 1 day of starvation to maintain concentrations. Death was assessed by quantiﬁcation of
sub-G1 populations by ﬂow cytometry (upper panel, *Po0.0345) and Caspase and Parp cleavage by western blot (lower panel). All bar
graphs in this ﬁgure represent averages of three independent experiments with error bars reﬂecting s.e.m.
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Oncogenetranscription in diverse cell types (Wildey et al., 2003;
Ramjaun et al., 2007; Ramesh et al., 2008; Yu et al.,
2008; Houde et al., 2009). We ﬁrst veriﬁed that the
TGFb ligand family regulates Bim mRNA in ES cells by
treating them with Activin, a TGFb family ligand to
which ES cells are responsive. Bim mRNA was increased
within 2h of Activin treatment in Bhd
þ/þ ES cells,
which did not occur in Bhd
 /  cells (Figure 5a). To
ascertain whether this effect was speciﬁc to Bim,w e
analyzed the mRNA levels of several other BH3-only
family members in response to Activin. Contrary to
Bim, Bid, BMF, and Bad mRNAs were not induced by
Activin in wild-type cells, and actually appeared
elevated in Bhd
 /  cells (Supplementary Figure 6a).
The latter ﬁnding was consistent with increased Bid and
BMF protein levels in Bhd
 /  cells, but appeared
opposite to that of Bad protein levels (Figure 3b). While
Pumaa mRNA was induced by Activin, this was not
BHD dependent as it occurred in both Bhd
þ/þ and
Bhd
 /  cells (Supplementary Figure 6a). Taken together,
these data identify Bim as a speciﬁc BH3-only mRNA
regulated by TGFb in a BHD-dependent manner.
To determine if TGFb-mediated transcriptional
defects were a general phenomenon in Bhd
 /  cells, we
Figure 5 Bhd
 /  ES cells exhibit phenotypes and transcriptional defects characteristic of TGFb-signaling components. (a) Bhd
þ/þ and
Bhd
 /  ES cells were cultured for 24h in N2B27 media, then stimulated with 10ng/ml of Activin. Bim mRNA levels were signiﬁcantly
induced in Bhd
þ/þ cells after stimulation, but not in Bhd
 /  ES cells (*P¼0.00864). (b) qRT–PCR analysis showing canonical TGFb
target genes PAI-1, p15, Lefty1, and Pitx2 are signiﬁcantly downregulated in multiple Bhd
 /  ES cell clones labeled 1, 2 and 3
(*Po0.04). (c) X-gal stained 70  image of (a) whole mount or 200  image of (b) sectioned yolk sac taken from a e10.5 Bhd
þ/m
embryo exhibiting high Bhd expression in visceral endoderm of the yolk sac. (d) 200  image of day 12 EBs showing Bhd
þ/þ EBs form
expanded cystic structures reminiscent of yolk sacs while Bhd
 /  EBs fail to do so. (e) qRT–PCR analysis on RNA from EBs, showing
two independent Bhd
 /  EBs (clones 1 and 2) fail to express maximal levels of mature yolk sac markers a-feto-protein (Afp) and
Trithioredoxin (Ttr). Averages represent maximal expression levels for each mRNA, which occurred between days 6 and 9 of EB
development (*Po1.0 10
 5 for both mRNAs). (f) Quantiﬁcation of benzediene-positive EBs that express hemoglobin (Hb) at day 10
in methylcellulose cultures demonstrating Bhd
 /  EBs fail to form erythroid lineages (*P¼2.32 10
 6). Data represent the average of
three independent experiments with error bars showing standard deviation. (g) qRT–PCR analysis of Gata-1 and CD34 mRNA
expression in day 10 EBs in methylcellulose cultures, which is signiﬁcantly reduced in Bhd
 /  EBs (Po4.49 10
 6).
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Oncogeneexamined the basal mRNA levels of several established
TGFb-transcriptional targets involved in diverse biolo-
gical processes. mRNA levels for the cell cycle regulator
p15, pro-apoptotic plasminogen inhibitor activator type
I( PAI-1)a n dLefty1 and Pitx2, which have develop-
mental roles were all lower in Bhd
 /  cells compared
with Bhd
þ/þ cells (Figure 5b). Other canonical TGFb
mRNA targets such as SnoN, p21, Col1a2, and Lefty2
were similarly downregulated in Bhd
 /  cells (Supple-
mentary Figure 6b). Other TGFb targets previously
implicated in cell cycle regulation and apoptosis were
unaffected in Bhd
 /  cells, including Gadd45b and p57,
while the death-associated protein kinase was actually
upregulated (Supplementary Figure 6c). Overall, these
data support a positive role for BHD in TGFb-mediated
transcription that governs biological processes impli-
cated in cancer such as apoptosis, cell cycle, and
differentiation.
TGFb ligands and receptors are required for normal
yolk sac vasculogenesis and embryonic hematopoiesis
in vivo, and in ES cell-derived cystic embryoid body (EB)
cultures in vitro (Dickson et al., 1995; Oshima et al.,
1996; Goumans et al., 1999; Larsson et al., 2001).
Interestingly, strong BHD expression was observed in
yolk sac visceral endoderm, as revealed by X-Gal
staining of E10.5 embryos heterozygous for the Bhd
m
allele (Figure 5c). To investigate whether BHD is
required for yolk sac development, we generated day
12 EBs from Bhd
þ/þ and Bhd
 /  ES cells. Bhd
 /  ES cells
failed to form expanded cystic EBs, which are reminis-
cent of mature yolk sacs in vivo (Figure 5d), or induce
mature yolk sac markers a-fetoprotein (Afp) and
Trithioredoxin (Ttr) (Doetschman et al., 1985)
(Figure 5e). To further evaluate the role of BHD in
embryonic hematopoietic stem cell development, we
generated Bhd
þ/þ and Bhd
 /  EBs in methylcellulose
cultures, which promotes the differentiation of hemato-
poietic lineages. Bhd
 /  EBs failed to form hemoglobi-
nized colonies at day 10 in culture (Figure 5f;
Supplementary Figure 6b) and exhibited severely
reduced mRNA levels of the erythroid gene Gata-1
and CD34 (a marker of both hematopoietic and
endothelial lineages) (Figure 5g). Interestingly, we
observed a delayed induction of the mesodermal marker
Brachyury, a super-induction of Fgf-5 and attenuated
maintenance of Hnf4 at later stages (Supplementary
Figure 7). However, these minor effects are unlikely to
explain the dramatic hematopoietic and yolk sac defects
of Bhd
 /  EBs, as maximal induction of these target
genes was still robust in Bhd
 /  EBs, increasing by orders
of magnitude.
Bhd
 /  cells exhibit hypo-acetylation of TGFb target gene
promoters, resulting in their death-resistance phenotype
Because BHD deﬁciency resulted in molecular and
phenotypic defects similar to TGFb receptor and ligand
mutants, we next investigated whether the transcrip-
tional defects occurred at the level of receptor-mediated
phosphorylation and nuclear translocation of Smad-
transcriptional regulators. Therefore, we examined
nuclear levels of phosphorylated and total receptor-
regulated Smad2 and the common partner Smad4,
which form a complex and translocate to the nucleus
upon cellular engagement of TGFb ligands (Zhang
et al., 1996). Western blot analysis did not reveal any
differences in basal or Activin-induced nuclear accumu-
lation of phospho-Smad2, total Smad2, or total Smad4
in Bhd
þ/þversus Bhd
 /  ES cells (Figures 6a and b).
Since Smads have previously been shown to activate
transcription via acetylation of Histone H3 at target
promoters, we performed chromatin immunoprecipita-
tions for acetylated Histone H3 at the well-characterized
Lefty1 promoter (Ross et al., 2006). Whereas Bhd
þ/þ ES
cells demonstrated a signiﬁcant increase in acetyl-H3
levels at the Lefty1 promoter following Activin treat-
ment, Bhd
 /  cells exhibited no response (Figure 6c).
A similar effect was observed at the promoter of PAI-1,
which has been implicated in the apoptotic response
(Kortlever et al., 2006; Lademann and Romer, 2008)
(Supplementary Figure 8a). This difference was not due
to a global reduction of acetyl-H3 levels, which
appeared unaffected based on western blot assays
(Figure 6d). To determine whether restoration of
acetylated Histone levels rescues Bhd
 /  cell defects,
Bhd
 /  cells were treated with the histone deacetylase
(HDAC) inhibitor Trichostatin A (TSA), which restored
mRNA levels of multiple TGFb target genes (PAI-1,
p15, and Bim), Bim protein levels and cell death (Figures
6e and f). TSA appeared to have variable effects on
other misregulated BH3-only proteins in Bhd
 /  cells
under nutrient deprivation (Supplementary Figure 8b).
First, nutrient deprivation itself changed protein levels
of some BH3-only proteins in Bhd
 /  cells, with BMF
actually decreasing and Bad equilibrating to wild-type
levels, in contrast to nutrient replete conditions
(Figure 3a). TSA appeared to have no effect on Pumaa
and Bid levels abundance under nutrient limitation,
while it slightly elevated Bad and BMF levels. It seems
unlikely, however, that Bad and BMF induction can
explain the effects of TSA, given the ability of Bim re-
expression alone to completely reverse the phenotype of
Bhd
 /  cells. In summary, BHD loss appears to
contribute to apoptotic resistance and TGFb-dependent
transcriptional defects via aberrations in chromatin
modiﬁcations at target gene promoters including Bim
(Figure 7).
Discussion
To date, the cellular and molecular mechanisms of
tumor suppression by BHD have remained elusive.
Uncovering BHD protein functions is particularly
challenging, given the lack sequence homology to any
known protein. In this study, we initially observed that
the major cellular consequence of BHD loss is apoptotic
resistance due to loss of Bim expression, a phenomenon
that can be observed in BHD-related renal tumors.
These ﬁndings prompted us to ask what signaling
pathways and/or transcriptional networks were implicated
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Oncogenein this phenotype. We initially examined the mTOR
pathway, as multiple published reports have shown
correlations between BHD loss and mTOR activity
(Hartman et al., 2009; Hasumi et al., 2009; Hudon et al.,
2010). While we did observe aberrant mTOR signaling
in Bhd
 /  cells, this was surprisingly unrelated to the
apoptotic defects.
We turned our attention to the TGFb pathway,
given its known role in regulating Bim transcription
and tumor suppression. For instance, in humans,
Smad4 germline mutations are associated with juvenile
polyposis syndrome, which predisposes individuals to
gastrointestinal cancers, and TGFbRI, TGFbRII and
activin receptor II are mutated or downregulated in a
broad spectrum of sporadic cancers (Levy and Hill,
2006). Epigenetic silencing of genes involved in TGFb
signaling has also been speciﬁcally observed in RCCs
(McRonald et al., 2009). Genetic ablation of these
signaling components in mice have conﬁrmed the tumor
suppressive function of this pathway in models of colon,
mammary, and pancreatic cancer (Massague, 2008). Our
data demonstrate that BHD loss results in yolk sac and
Figure 6 Loss of BHD results in HDAC-mediated silencing of TGFb-transcriptional targets. Western blot of nuclear extracts
showing (a) basal or (b) Activin-induced levels of nuclear phospho-smad2, Smad2, and Smad4 are unaffected in Bhd
 /  ES cells. Non-
speciﬁc (NS) band is shown as a loading control. (c) qRT–PCR using primers located in the Lefty1 promoter on genomic DNA
immunoprecipitated with acetyl-histone H3 antibody from ES cells stimulated with activin for 1h following 24h culture in N2B27.
(d) Western blot showing total levels of acetyl-histone H3 are unaffected in Bhd
þ/þ versus Bhd
 /  cells with and without Activin
treatment. (e) Treatment of Bhd
 /  cells with TSA restores mRNA levels of PAI-1, p15, and Bim as shown by qRT–PCR analysis of
mRNA expression levels (*Po0.0362). (f) Treatment of Bhd
 /  ES cells with TSA rescues the Bhd
 /  cellular death-resistance
phenotype and Bim expression as shown by analysis of sub-G1 populations (above, *P¼0.000145) and western blot for Bim, and
Caspase and Parp cleavage (below).
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and ligand mutants. These phenotypes correlate with
global aberrations in TGFb-mediated transcription,
which appear to occur downstream of nuclear accumu-
lation of phosphorylated Smads. Our data indicate this
defect is most likely due to HDAC-mediated effects on
chromatin at Smad-dependent promoters, given the
ability of TSA to reverse the biological and molecular
defects of Bhd
 /  cells (Figure 7). Further work will be
needed to elucidate the nature of these effects.
Previous studies have suggested a contradictory role
for mTOR in BHD-related tumorigenesis, showing that
BHD loss can result in either upregulation or down-
regulation of mTOR signaling. These studies have been
largely correlative and have not demonstrated a
causative relationship between the signaling aberrations
and biological outcomes (Baba et al., 2006; Hartman
et al., 2009; Hasumi et al., 2009; Hudon et al., 2010).
While we observed increased mTOR signaling in Bhd
 / 
ES cells, as reported for late-stage kidney tumors taken
from a BHD mouse model, this phenomenon appeared
unrelated to the observed apoptotic resistance. We
speculate that effects of BHD loss on mTOR signaling
likely result from compensation and/or crosstalk with
more proximal defects in TGFb signaling.
Collectively, the data presented here establish a novel
model whereby BHD exerts its major tumor suppressive
effect through TGFb-mediated transcriptional output to
regulate cell-intrinsic apoptosis. A recent publication
has further supported this model, suggesting TGFb-
dependent transcriptional defects in a human BHD-
derived tumor cell line (Hong et al., 2010). This study
demonstrated that BHD deﬁciency results in decreased
levels of TGFb pathway signaling components them-
selves including the ligands TGFb-2 and Inhibin b A
and Smad3. This contrasts with our data that demon-
strate an effect of BHD downstream of signaling, on
canonical Smad target gene promoters. Further, the
report by Hong et al. suggested that TGFb-2 stimulates
cell growth and survival in the absence of BHD, while
the TGFb ligand Activin does the opposite. The latter is
surprising in light of our ﬁndings, given the failure of
BHD null ES cells to mount any transcriptional
response to Activin treatment. This discrepancy likely
derives from differential cell type, dosage and/or length
of treatment, which has been well documented for
TGFb ligands (Massague, 2008). In any case, these
molecular defects likely extend to other tumor-promot-
ing effects such as cell-type speciﬁc proliferative
advantages, due to p15 loss, and stromal alterations in
BHD-related tumors in vivo (Massague, 2008). Although
our in vitro study did not uncover a role for BHD in
proliferation, this is likely due to the unusual cell cycle
machinery of ES cells, which is refractory to cyclin-
dependent kinase inhibitors (Savatier et al., 1996; Faast
et al., 2004). It is probable that BHD loss and
consequent defective TGFb-mediated signaling in vivo
results in a proliferative advantage. Collectively, these
ﬁndings suggest several targeted therapeutics for the
treatment of BHD-related tumors, as well as sporadic
cases of cystic lung disease and RCC, including BH3-
only mimetics, autophagy inhibitors, and HDAC
inhibitors, which are all currently in clinical use for the
treatment of other types of cancer.
Materials and methods
Sub-G1 quantiﬁcation
Cells were ﬁxed and stained as previously described, then
ﬂuorescence was measured by ﬂow cytometry (Riccardi and
Nicoletti, 2006). At least 10000 cells were counted for each
experiment and data were analyzed using FlowJo software.
X-Gal staining of tissues and embryos
X-gal staining was carried out as previously described for both
cells and whole mount tissues ﬁxed in 4% paraformaldehyde
according to the Sanger Institute gene-trap protocol.
X-gal stained yolk sac sections came from tissue snap-frozen
in OCT.
Alkaline phosphatase staining
Cells were stained using the Alkaline Phosphatase Detection Kit
from Millipore (Bellerica, MA, USA) according to the manu-
facturer’s instructions.
RNA isolation and qRT
RNA was extracted using Qiagen (Valencia, CA, USA)
RNeasy columns with DNAase treatment and cDNA was
written off B1mg of RNA per reaction using the ABI (Foster
Figure 7 Model: Loss of BHD leads to increased HDAC-
dependent repression of Smad-speciﬁc promoters. (a) In the
presence of BHD, Smad-dependent transcription is active, allowing
transcription of pro-apoptotic genes like Bim and anti-proliferative
genes like p15 to promote tumor suppression. (b) However, when
BHD is lost, Smad-dependent transcription is repressed and
apoptotic and anti-proliferative responses are lost, leading to
tumor formation.
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OncogeneCity, CA, USA) one-step RT–PCR Master Mix. qRT–PCR
reactions were run in triplicate on an ABI 7900HT machine for
each experiment, utilizing either SYBR green or Taqman primer
probe sets as noted in Supplementary Materials. All target
mRNA levels were normalized to b-actin or 18s expression
levels. All qRT–PCR data reﬂect average mRNA levels from
three independent RNA extractions and reverse transcription
reactions with error bars showing standard error of the mean.
Protein extraction and western blotting
Whole-cell lysates were prepared using a buffer containing
120mM NaCl, 1mM EDTA, 10mM pyrophosphate, 10mM
glycerophosphate, 50mM NaF, 1% Triton, and freshly added
protease inhibitor cocktail tablets from Roche (Basel, Switzerland)
and 2mM orthovanadate. Nuclear extracts were prepared
using the Active Motif Nuclear Extraction kit, with 500mM
NaCl added after nuclease digestion followed by sonication of
nuclear extracts. Lysates were run on polyacrylamide gels,
transferred to nitrocellulose, blotted using standard protocols,
and visualized on ﬁlm using HRP-conjugated secondary
antibodies and ECL reagent.
Cell size measurements
Cell size was measured using a Z2 Coulter particle size analyzer.
At least 10000 cells were measured for each experiment.
Characterization of gene-trapped ES cells and mice
Bhd
þ/m ES cells were obtained from Bay Genomics and Bhd
þ/ 
ES cells were obtained from the German Gene Trap
Consortium, with isogenic parental Bhd
þ/þ lines being
obtained from each respective source. Gene-trap insertions
were mapped by ﬁrst PCR amplifying the boundary of the
fusion transcript using primers within the 30 end of the trap
cassette and within the sequence tag, on cDNA generated from
heterozygous ES cells. The precise genomic location of the
cassette was mapped by direct PCR ampliﬁcation of the
respective intronic-trap cassette boundary using primers in the
exon just upstream from the insertion and within the 50 end of
the trap cassette. Southern blots were carried out on either
PvuII or BamHI-digested DNA on Bhd
þ/m or Bhd
þ/  ES cell,
respectively, with 50 end-directed probes being generated by
PCR ampliﬁcation from genomic DNA and subsequent TOPO
cloning. Bhd
þ/m mice were generated and intercrossed and
embryo collection was performed as previously described
(Covello et al., 2006; Hartman et al., 2009)
Proliferation assay
In all, 5 10
4 cells were plated in a gelatinized 12-well plate
and counted using the Countess automatic counter from
Invitrogen (Carlsbad, CA, USA) each day after plating.
Immunohistochemistry
Parafﬁn-embedded tissue was immunostained using a rabbit
polyclonal anti-Bim antibody from Novus following antigen
retrieval in sodium citrate solution and developed using
diaminobenzidine.
Embryoid bodies
For suspension cultures, 8 10
6 ES cells were plated in 10cm
bacterial dishes in DMEM containing 10% FBS and
b-mercaptoethanol. Media was changed every other day, with
EBs being split 1:2 on day 3. Methylcellulose cultures and
benezidiene staining were performed as previously described
(Cooper et al., 1974; Adelman et al., 1999).
Northern blotting
Northern blots for miRNAs were done as previously described
(Gruber et al., 2009).
Chromatin immunoprecipitation
In all, 1 10
6 ES cells were ﬁxed for 10min in 1%
formaldehyde for 10min at room temperature. Crosslinking
was quenched with 125mM glycine for 5min, then cells were
lysed and sonicated to shear DNA for 3min with on/off pulses
using a Fisher Sonic Dismembranator Model 500 at 20%
power. Chromatin immunoprecipitation was carried using the
Imgenex QuikChIP kit according to the manufacturer’s
instructions using a pan acetyl-H3 antibody from Millipore.
Eluted protein/DNA complexes were puriﬁed by phenol/
chloroform extraction and ethanol precipitation.
Statistics
All P-values were generated using a two-tailed Student’s t-test.
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